Good Clinical Practice Guide
Results 1 to 5 of 5

Thread: IMP Transfer from one study site to another

Hybrid View

Previous Post Previous Post   Next Post Next Post
  1. #1
    Forum Member
    Join Date
    Nov 2011
    Posts
    183
    Also, of course a risk assessment on the IMP itself. The QP will want to assess whether the IMP still remains inside specification before transferring to another site (as per Annex 13 above). Hence your SOP will need to include this assessment and whether IMPs that are more sensitive (such as those with only limited stability data, or those which need special handling , such as cool chain IMP) would be unlikely candidates for inter-site transfer.
    Last edited by MHRA Moderator; 6th Sep 2012 at 03:23 PM.

Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts
  •